Diplomat Pharmacy Inc (DPLO) Given Consensus Rating of “Hold” by Analysts
Diplomat Pharmacy Inc (NYSE:DPLO) has been given an average recommendation of “Hold” by the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $21.25.
DPLO has been the subject of several recent analyst reports. William Blair cut Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research note on Monday, January 7th. ValuEngine cut Diplomat Pharmacy from a “sell” rating to a “strong sell” rating in a research note on Monday, February 4th. Robert W. Baird upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $10.00 to $15.00 in a research note on Friday, December 7th. Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 27th. Finally, Morgan Stanley lowered their price target on shares of Diplomat Pharmacy from $20.00 to $18.00 and set an “equal weight” rating for the company in a report on Monday, December 3rd.
NYSE DPLO traded down $0.01 on Friday, hitting $13.89. 344,800 shares of the company’s stock were exchanged, compared to its average volume of 614,410. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.95 and a quick ratio of 0.66. Diplomat Pharmacy has a 52 week low of $12.30 and a 52 week high of $28.74. The stock has a market capitalization of $1.03 billion, a PE ratio of 16.54 and a beta of 0.98.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: Options Trading
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.